Log in to search using one of your social media accounts:

 

J & J's Stelara shows promise against lupus in study
(Reuters) - Johnson& Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - November 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Risankizumab outperforms ustekinumab in psoriasis trial
The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (Source: Dermatology Times)
Source: Dermatology Times - October 19, 2017 Category: Dermatology Source Type: news

FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens
For at least two thirds of patients aged 12 to 17 years who were treated with ustekinumab, cleared skin or minimal psoriasis was achieved at week 12 in a phase 3 study.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 16, 2017 Category: Universities & Medical Training Tags: Dermatology News Alert Source Type: news

Janssen announces u.s. fda approval of stelara ® (ustekinumab) for the treatment of adolescents with moderate to severe plaque psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 14, 2017 Category: Pharmaceuticals Source Type: news

J & J psoriasis drug gets expanded U.S. approval for teens
(Reuters) - Johnson& Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition. (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Horsham, Pa., October 13, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2017 Category: Drugs & Pharmacology Source Type: news

NICE approves new type of treatment for Crohn ’s disease
Following NICE recommendations, patients with Crohn ’s disease will have routine NHS access to drug ustekinumab, which offers a new way of treating the condition. (Source: NHS Networks)
Source: NHS Networks - June 22, 2017 Category: UK Health Source Type: news

UK NICE recommends Janssen ’s Ustekinumab treatment for Crohn’s disease
The UK ’s National Institute for Health and Care Excellence (NICE) has recommended Janssen’s Ustekinumab for the treatment of patients with moderate-to-severe Crohn’s disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 18, 2017 Category: Pharmaceuticals Source Type: news

Risankizumab More Effective in Psoriasis Than Ustekinumab in Early Trial Risankizumab More Effective in Psoriasis Than Ustekinumab in Early Trial
Selective inhibition of IL-23 with risankizumab may be more effective in treating psoriasis than the less specific ustekinumab; more studies are needed to confirm results and assess.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 19, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

One Biologic Bests Another in Head-to-Head Psoriasis Trial
(MedPage Today) -- Taltz turns in better results than Stelara on severity indices (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 6, 2017 Category: Dermatology Source Type: news

New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira ® in Treatment of Moderate to Severe Plaque Psoriasis
Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA ® in the Treatment of Moderate to Severe Plaque Psoriasis (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 3, 2017 Category: Pharmaceuticals Source Type: news

Janssen Submits Application Seeking FDA Approval Of Stelara ® (Ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 17, 2016 Category: Pharmaceuticals Source Type: news

Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., Dec. 16, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Biotech, Inc. (Janssen) announced today the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval ... Biopharmaceuticals, Dermatology, FDA Janssen, STELARA, ustekinumab, Psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 16, 2016 Category: Pharmaceuticals Source Type: news

Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
STELARA® offers a new approach to treating Crohn's disease in Canada, which has one of the highest rates of this inflammatory bowel disease worldwide1 TORONTO, Dec. 14, 2016 (Healthcare Sales & Marketing Network) - Janssen Inc. announced today that... Biopharmaceuticals, Gastroenterology, Regulatory Janssen Pharmaceutical, STELARA, ustekinumab, Crohn's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2016 Category: Pharmaceuticals Source Type: news

Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn ’s Disease
Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - November 29, 2016 Category: Pharmaceuticals Source Type: news

Drug Stelara May Ease Crohn's Disease
Title: Drug Stelara May Ease Crohn's DiseaseCategory: Health NewsCreated: 11/17/2016 12:00:00 AMLast Editorial Review: 11/18/2016 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 18, 2016 Category: Nutrition Source Type: news

Drug Stelara May Ease Crohn's Disease
Medication is potentially helpful for those who didn't find relief from other treatments, researchers say (Source: WebMD Health)
Source: WebMD Health - November 17, 2016 Category: Consumer Health News Source Type: news

Drug Stelara May Ease Crohn's Disease
Medication is potentially helpful for those who didn't find relief from other treatments, researchers say Source: HealthDay Related MedlinePlus Pages: Crohn's Disease, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 17, 2016 Category: Consumer Health News Source Type: news

Drug Stelara May Ease Crohn's Disease
THURSDAY, Nov. 17, 2016 -- People with moderate to severe Crohn's disease who haven't responded to other treatments may benefit from the drug ustekinumab (Stelara), a new study suggests. Stelara is a monoclonal antibody that blocks the action of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 17, 2016 Category: Journals (General) Source Type: news

Arthritis drug significantly effective in treating Crohn's disease, study finds
Ustekinumab, a human antibody used to treat arthritis, significantly induces response and remission in patients with moderate to severe Crohn ’s disease, researchers have shown that. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 17, 2016 Category: Science Source Type: news

Ustekinumab Effective in TNFi-Refractory Crohn's Disease Ustekinumab Effective in TNFi-Refractory Crohn's Disease
Ustekinumab induced early response and sustained remission at 44 weeks significantly better than did placebo, with a similar side effect profile, three trials have found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 17, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Phase 3 Study Results Supporting U.S. FDA and European Commission Approvals of STELARA ® in the Treatment of Moderately to Severely Active Crohn's Disease Published in The New England Journal of Medicine
Data from Three Pivotal Phase 3 Studies Detail Efficacy and Safety of First and Only Anti-interleukin-12 and 23 Monoclonal Antibody in Inducing and Maintaining Clinical Response and Remission after One Year of Treatment (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 16, 2016 Category: Pharmaceuticals Source Type: news

Study finds arthritis drug significantly effective in treating Crohn's disease
(University of California - San Diego) Researchers at University of California San Diego School of Medicine have shown that ustekinumab, a human antibody used to treat arthritis, significantly induces response and remission in patients with moderate to severe Crohn's disease. Results of the clinical trial will appear in the Nov. 16 issue of the New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2016 Category: Global & Universal Source Type: news

European Commission Approves Stelara ® (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease
First Interleukin (IL)-12/23 Inhibitor Licensed For Crohn ’s Disease (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 11, 2016 Category: Pharmaceuticals Source Type: news

Head-to-Head Results Compare Biologics for Psoriasis Head-to-Head Results Compare Biologics for Psoriasis
For patients with moderate to severe plaque psoriasis, ixekizumab is more effective than ustekinumab at 12 weeks, researchers report, but a longer-term study is needed to confirm this.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2016 Category: Consumer Health News Tags: Dermatology News Source Type: news

Stelara Given the Go-Ahead for Crohn's
(MedPage Today) -- Effective in patients with and without prior anti-TNF failure (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 26, 2016 Category: American Health Source Type: news

FDA Clears Ustekinumab (Stelara) for Crohn's Disease FDA Clears Ustekinumab (Stelara) for Crohn's Disease
In clinical trials, most patients who responded to induction therapy with ustekinumab and continued treatment achieved remission of symptoms.FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 26, 2016 Category: Allergy & Immunology Tags: Gastroenterology News Alert Source Type: news

FDA approves J & J's autoimmune drug Stelara for Crohn's disease
(Reuters) - Johnson& Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease. (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Stelara (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn's Disease
HORSHAM, Pa., Sept. 26, 2016 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn's disease in adults (18... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 26, 2016 Category: Drugs & Pharmacology Source Type: news

Stelara Aids in PsA Regardless of Previous Tx (CME/CE)
(MedPage Today) -- Patients who had used anti-TNFs still benefited from ustekinumab (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 11, 2016 Category: Rheumatology Source Type: news

Boehringer Ingelheim ’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study
Boehringer Ingelheim ’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Boehringer Ingelheim ’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study
Boehringer Ingelheim ’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Ustekinumab misses primary endpoint in atopic dermatitis
SCOTTSDALE, ARIZ. – Treatment with ustekinumab did not result in significant improvements in atopic dermatitis after 16 weeks, compared with placebo in a phase II study of adults with moderate to severe atopic dermatitis, Dr. Patrick Brunner reported at the annual meeting of the Society for... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 30, 2016 Category: Dermatology Source Type: news

Giant Cell Arteritis: Ustekinumab Shows Activity in Early TrialGiant Cell Arteritis: Ustekinumab Shows Activity in Early Trial
Ustekinumab was associated with lower steroid doses in some patients with GCA and reduced arterial wall thickening. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 12, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Ustekinumab Improves Spondylitis in Psoriatic ArthritisUstekinumab Improves Spondylitis in Psoriatic Arthritis
The anti-interleukin (IL)-12/IL-23 monoclonal antibody ustekinumab improves signs and symptoms of spondylitis in patients with psoriatic arthritis, according to a post-hoc analysis of data from the PSUMMIT-1 and PSUMMIT-2 trials. Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 3, 2016 Category: Orthopaedics Tags: Rheumatology News Source Type: news

J&J psoriasis drug Stelara eases Crohn's disease in second trial
(Reuters) - Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial, the company said on Friday, bolstering prospects of its approval for the additional use. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Efficacy and Safety Results from Second STELARA® Phase 3 Induction Study (UNITI-1), the Largest Conducted to Date in Patients Refractory to TNF Inhibitors, Presented at the 11th Congress of ECCO AMSTERDAM, March 18, 2016 -- (Healthcare Sales & Marke... Biopharmaceuticals, GastroenterologyJanssen, STELARA, ustekinumab, Crohn's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2016 Category: Pharmaceuticals Source Type: news

Novartis’ Cosentyx® superior to Stelara in delivering lasting skin clearance for psoriasis patients
Cosentyx launched as first-line systemic indication for psoriasis in UK in 2015 and recently approved for psoriatic arthritis and ankylosing spondylitis in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 9, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Dermatology Patient care Research ankylosing spondylitis Cosentyx Latest News PASI psoriatic arthritis Source Type: news

Targeted Treatment May Reverse Alopecia AreataTargeted Treatment May Reverse Alopecia Areata
The psoriasis drug ustekinumab can spur hair regrowth and normalize immune function in patients with alopecia areata, according to the results of a study in three patients. Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 14, 2015 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Janssen seeks approval for Stelara in US and Europe to treat Crohn's disease
Janssen Biotech and Janssen-Cilag International (Janssen) have submitted two applications in the US and Europe for approval of Stelara (ustekinumab) to treat adults with moderately to severely active Crohn's disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 1, 2015 Category: Pharmaceuticals Source Type: news

Landmark clinical trial of a novel combination treatment for type 1 diabetes
(McGill University) Investigators at Montreal's Lady Davis Institute at the Jewish General Hospital and McGill University Health Centre have announced the start of a landmark clinical study aimed at restoring normal insulin secretion in people with longstanding type 1 diabetes. The treatment combines INGAP Peptide (ExsulinTM), which stimulates growth of the insulin secreting islets, and ustekinumab (SteleraTM), a drug approved for the treatment of psoriasis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 25, 2015 Category: Global & Universal Source Type: news

EADV: Investigational biologic rocks psoriasis world
COPENHAGEN – An investigational biologic agent that selectively inhibits the p19 subunit of interleukin-23 was the talk of the 2015 EADV congress based upon its striking outperformance of ustekinumab in a head-to-head phase II study in psoriasis patients. Not only did the investigational agent,... (Source: Skin and Allergy News)
Source: Skin and Allergy News - October 25, 2015 Category: Dermatology Source Type: news

Stelara: A Coming Option for Crohn's? (CME/CE)
(MedPage Today) -- More than half of patients had clinical responses by week six of treatment (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 21, 2015 Category: Gastroenterology Source Type: news

J&J's Stelara Succeeds in Phase III Crohn's Disease TrialJ&J's Stelara Succeeds in Phase III Crohn's Disease Trial
Johnson & Johnson's Stelara (ustekinumab) was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 20, 2015 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news

Johnson & Johnson's Stelara succeeds in Phase III Crohn's disease trial
(Reuters) - Johnson & Johnson's Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Novel Interleukin 17 Antibody Quickly Reduces PsoriasisNovel Interleukin 17 Antibody Quickly Reduces Psoriasis
Brodalumab cleared 100% of plaque in twice as many patients as ustekinumab, but the safety profile needs more study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2015 Category: Consumer Health News Tags: Dermatology News Source Type: news

Brodalumab psoriasis results published, development plans continue
Brodalumab met all primary endpoints against its first-in-class rival, ustekinumab, and against placebo in two phase III trials of more than 3,700 patients with moderate to severe plaque psoriasis, investigators reported in the New England Journal of Medicine. The results of the two studies,
Source: Skin and Allergy News - September 30, 2015 Category: Dermatology Source Type: news

Improvements seen in adolescent psoriasis with ustekinumab
The CADMUS trial showed improvements in moderate to severe psoriasis in adolescent patients 12 years or older treated with ustekinumab, a study showed. Treatment of psoriasis in pediatric patients is complicated by the limited number of approved treatments, despite approximately one-third of... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 30, 2015 Category: Dermatology Source Type: news

Ustekinumab Found to Be Effective in Adolescents With PsoriasisUstekinumab Found to Be Effective in Adolescents With Psoriasis
Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 1, 2015 Category: Dermatology Tags: Dermatology News Source Type: news

Secukinumab Beats Ustekinumab in Moderate to Severe PsoriasisSecukinumab Beats Ustekinumab in Moderate to Severe Psoriasis
Psoriasis patients experienced greater efficacy and improvement in health-related quality of life (HRQoL) on secukinumab than they did on ustekinumab in a new trial funded by Novartis. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 30, 2015 Category: Dermatology Tags: Dermatology News Source Type: news